Bildkälla: Stockfoto

Lidds Q1: Focus on out-licensing - Redeye

Redeye maintains a positive view of LIDDS and the company's capability to execute its out-licensing strategy and develop its clinical program based on the Nanozolid-platform, after the Q1 report today.

Redeye maintains a positive view of LIDDS and the company's capability to execute its out-licensing strategy and develop its clinical program based on the Nanozolid-platform, after the Q1 report today.
Börsvärldens nyhetsbrev
ANNONSER